Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 15/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 13/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.41 |
| ▸ | NPM1 | P06748 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22972835 | 1.00 | TLR9 (0.42) | TLR9TLR7PIK3CDPIK3CAPIK3CB | |
| SCHEMBL2163138 | 0.90 | KDM4E (0.47) | TLR9TLR7NPM1ALK | |
| SCHEMBL12323631 | 0.90 | TLR9 (0.41) | TLR9TLR7PIK3CDPIK3CAPIK3CB | |
| SCHEMBL2162454 | 0.87 | TLR9 (0.40) | TLR9TLR7 | |
| SCHEMBL22972838 | 0.87 | TLR9 (0.40) | TLR9TLR7 | |
| SCHEMBL2162653 | 0.84 | TLR9 (0.38) | TLR9TLR7NPM1ALK | |
| SCHEMBL2164515 | 0.80 | DGAT1 (0.42) | PIK3CDPIK3CAPIK3CBNPM1ALK | |
| SCHEMBL2163296 | 0.74 | ALK (0.60) | NPM1ALK | |
| SCHEMBL2162795 | 0.74 | ALK (0.38) | PIK3CDPIK3CAPIK3CBNPM1ALK | |
| SCHEMBL20515380 | 0.73 | IKBKB (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2550255-B1 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | LILLY CO ELI (US) | 2016-04-27 | — | — | EP | disclosed |
| EP-2550255-B1 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | LILLY CO ELI (US) | 2016-04-27 | — | — | EP | disclosed |
| WO-2011119565-A1 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-09-29 | — | — | WO | disclosed |
| US-20110182812-A1 | Imaging Agents for Detecting Neurological Disorders | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110182812-A1 | Imaging Agents for Detecting Neurological Disorders | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110182812-A1 | Imaging Agents for Detecting Neurological Disorders | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110182812-A1 | Imaging Agents for Detecting Neurological Disorders | MAPT, APP, PSEN1 | TLR9 4824/4885TLR7 4767/4885PIK3CD 3730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.